Royalty Pharma plc Stock News

Investors looking for stocks in the Financial - Miscellaneous Services sector might want to consider either Royalty Pharma (RPRX) or Blackstone Inc. (BX). But which of these two companies is the best

Royalty Pharma PLC (NASDAQ:RPRX ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors interested in Financial - Miscellaneous Services stocks are likely familiar with Royalty Pharma (RPRX) and Brookfield Asset Management (BAM). But which of these two stocks presents investors

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S

Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The Vertex franchise is a significant contributor to

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnership with Ferring Pharmaceuticals, investing $300 mi

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol

Royalty Pharma (RPRX) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago.

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Royalty Pharma and JD.com both provide investors with above-average dividend yields. Royalty Pharma's business model relies on royalty payments, making it suitable for income investors.

Shares of biopharmaceutical royalty concern Royalty Pharma plc have fallen 45% from their all-time high as inflation and a potential revenue decline from its number one asset weigh. Vertex Pharmaceuti

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. f

Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.